Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 42Gastrointestinal 40Head & Neck 11Thoracic 10Gynecologic 9Other hematologic neoplasm 8Tumor-Agnostic 7Genitourinary 6Lymphoid 4Endocrine 3Sarcoma 2CNS 2Plasma cell 1Other solid neoplasm 1Other neoplasm 1Other 1NET 1Dermatologic 1Classical hematology 1

Conditions

Osteolysis 1Multiple Myeloma 1Motor Activity 1

Interventions

Dexamethasone 870Lenalidomide 456Bortezomib 454Cyclophosphamide 365Melphalan 271Calcium Dobesilate 262daratumumab 233pomalidomide 207carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74Cyclosporine 68isatuximab 67auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 56Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Control Groups × Plasma cell × Clear all
NCT07026799 2025-06-18

GMMG-HD8-INDEX

University Hospital Heidelberg

Phase NA Active not recruiting
50 enrolled
Plasma cell

Motor Activity, Multiple Myeloma, Osteolysis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡